Medicare Part B Costs and Changes in 2027

• President Trump announced on October 2, 2026 that more than 20 million Medicare enrollees will receive one-time $90 payments from the Medicare Improvement Fund, deposited in early October.
• The standard 2026 Part B premium is $202.90 a month, up $17.90 (9.7%) from $185.00 in 2025, while the 2026 Social Security COLA was just 2.8%.
• The 2026 Social Security and Medicare Trustees Report projects the 2027 premium at $209.50 (3.5% higher); private forecasters expect $216 to $219.
• Projected 2027 IRMAA surcharges reach $502.60 a month above the standard premium at the top income tier, based on 2025 tax returns.
• CMS finalized the mandatory GLOBE drug-pricing model on September 30, 2026, launching January 1, 2027 in about 25% of original Medicare areas.

On October 2, 2026, President Donald Trump announced that more than 20 million Medicare enrollees will receive a $90 payment from the federal government. The money comes from the Medicare Improvement Fund, a $2 billion pool Congress set aside for fee-for-service improvements that no prior administration had used, according to a White House fact sheet. Most eligible seniors receive it by direct deposit in early October; those without direct deposit get a check mailed to the address on file with Medicare.

Here is the number that puts the payment in perspective. The standard Medicare Part B premium in 2026 is $202.90 a month, up $17.90 from $185.00 in 2025, a 9.7% increase. The $90 one-time transfer amounts to about two weeks of that monthly cost. It is not a permanent reduction, and the announcement does not clarify whether the fund can support a repeat payment in a future year.

Two groups are excluded from the payment: beneficiaries whose premiums Medicaid already covers, and anyone who pays the Income-Related Monthly Adjustment Amount (IRMAA), the income-based surcharge added on top of the standard premium. That second exclusion is the counterintuitive part. The enrollees paying the largest Part B bills, some more than $689 a month in 2026, receive no offset at all.

Market Overview

Healthcare and retirement-linked assets finished the week of September 29 to October 2, 2026 on firm footing. The S&P 500 (^GSPC) closed Friday at 7,722.72, up 56.27 points (+0.73%). The Nasdaq Composite (^IXIC) added 319.26 points (+1.19%) to finish at 27,190.86, a new 52-week high. The Dow Jones Industrial Average (^DJI) rose 250.40 points (+0.49%) to 51,176.96.

Those closes extended a broad annual advance: the S&P 500 is up 14.99% over the trailing year, the Nasdaq 19.36%, and the Dow 9.45%. The S&P 500’s 52-week low of 6,368.85 came on March 23, 2026; its 52-week high of 7,785.76 was set August 10, 2026, leaving the index about 0.8% below its peak. The Dow sits further from its own 52-week high of 54,036.93, reached August 3, 2026.

The Medicare news this week affects household budgets of roughly 20 million Part B enrollees rather than moving the market indexes. For the rate and inflation context that shapes both COLA and premium, see our September FOMC analysis.

What Medicare Part B Costs Next Year

The 2026 premium increase outpaced the Social Security cost-of-living adjustment (COLA) that beneficiaries received for the same year. The 2026 COLA was 2.8%, which added about $56 a month to a $2,000 benefit. The $17.90 Part B increase used up roughly a third of that raise, which is why the net gain reaching many retirees’ bank accounts was far smaller than the headline COLA indicated.

The 2027 picture looks milder on paper, but forecasts differ. The 2026 Social Security and Medicare Trustees Report, released July 28, 2026, projects the standard Part B premium at $209.50 for 2027, a 3.5% increase and $6.60 more per month. The Part B deductible is projected to rise to $292 from $283, a 3.2% increase. Private forecasters expect more: estimates compiled by 24/7 Wall St. put the 2027 premium between $216 and $219, citing the Trustees’ pattern of underestimating costs. CMS publishes binding figures in its November fact sheet.

The timing affects cash flow. Social Security announces the 2027 COLA in October, while CMS reveals the Part B premium in November. The January deposit is the first that reflects both changes at once, since COLA applies to the December benefit paid in January.

Because most beneficiaries have Part B withheld from their Social Security check, the net raise is smaller than the headline COLA. On an illustrative $2,000 gross benefit with a 3.5% COLA ($70), a projected $6.60 Part B increase would reduce the amount reaching the bank to roughly $63.40. If the private forecast of $216 to $219 proves right, the deduction is far larger, and the net gain shrinks accordingly. The hold harmless provision at 42 U.S.C. §1395r(f) limits the standard premium increase so it cannot reduce a Social Security payment year over year, but it does not apply to IRMAA payers, new 2027 enrollees, or beneficiaries whose Part B is not deducted from Social Security.

2026 vs. 2027 Cost Comparison

IRMAA and High-Income Enrollees

The standard premium is not the ceiling. Projected 2027 IRMAA surcharges, per Kiplinger’s compilation from The Finance Buff and the 2026 Trustees Report, range from $83.70 a month at the first tier for single filers with 2025 modified adjusted gross income between $112,001 and $142,000, up to $502.60 at the top tier for income of $500,000 or more. The highest bracket remains fixed at $500,000 for individuals and $750,000 for joint filers until 2028; the lower four are indexed to inflation. Top-tier Part B cost in 2026 reached $689.90 a month.

IRMAA uses a two-year lookback: 2027 surcharges are based on income reported on the beneficiary’s 2025 return. A one-time capital gain, a home sale, or a shift from joint to single filing after a spouse’s death can push a retiree into a higher tier without any change in ongoing income. The 2027 projection includes an additional complication: the Bureau of Labor Statistics did not publish official October 2025 CPI-W data because of a federal government shutdown, so CMS has to estimate the missing data point to run its inflation formula.

This is why the October Medicare Improvement Fund payments exclude IRMAA payers entirely. The exclusion directs the $90 toward fixed-income enrollees most sensitive to the standard premium, but it also means beneficiaries paying the largest Part B bills receive no offset at all.

GLOBE Model and Part B Drug Costs

CMS finalized the mandatory Global Benchmark for Efficient Drug Pricing (GLOBE) Model on September 30, 2026. The program launches January 1, 2027 and runs through March 31, 2032, with rebate invoicing continuing until March 31, 2034. It covers beneficiaries in a randomly selected subset of geographic areas, about 25% of those with original Medicare as primary coverage.

Instead of the current domestic benchmark, GLOBE calculates rebates under the Part B Drug Inflation Rebate Program using international net pricing from reference countries including Canada, Germany, Japan, and the United Kingdom. Covered drugs are single-source drugs and sole-source biologicals in oncology, rheumatology, immunology, ophthalmology, and endocrinology classes where annual original Medicare spending exceeds $100 million. Biosimilars and their reference biologicals are excluded once a biosimilar enters the US market, as are orphan-only drugs, plasma-derived products, and certain cell and gene therapies.

CMS cites the widening gap to justify the model: the agency says Americans pay more than four times as much for brand-name prescription drugs as people in other developed countries, though its own GLOBE model page puts the gap at three times for the same medications. Rebates go to the Medicare Supplementary Medical Insurance Trust Fund. Reduced coinsurance for GLOBE drugs begins April 1, 2027, linking beneficiary out-of-pocket costs to the international benchmark.

The mandatory design is the contentious part. Manufacturers of eligible drugs cannot opt out, and the model is limited to 25% of beneficiaries, which restricts both its savings and its generalizability. Whether lower rebates lead to lower provider payments without affecting access is the open question CMS says the model is meant to test.

Outlook and Key Events Ahead

Three dated milestones will settle most of the 2027 cost questions, and each has a concrete consensus to track.

Economic calendar. The Social Security Administration is expected to announce the 2027 COLA on October 14, 2026, once September CPI-W data is final. Nonpartisan forecasts cluster around 3.5% to 3.6%. The 2026 COLA was 2.8%, so a mid-3% figure would be the largest raise in several years. Also watch September CPI and PPI prints due in mid-October, which feed both the COLA calculation and the inflation assumptions behind the Part B premium projection. August CPI came in at 3.4%, down from 3.5% in July.

Medicare premium announcement. CMS is expected to publish the binding 2027 Part B premium and deductible in its November annual fact sheet. The $209.50 Trustees projection and the $216 to $219 private forecast bracket the possible range. This single number, combined with COLA, determines the January deposit for roughly 70 million Social Security recipients.

Drug pricing implementation. GLOBE’s January 1, 2027 launch puts manufacturers on a fixed clock. Reduced coinsurance for beneficiaries in selected areas begins April 1, 2027, the first measurable test of whether international benchmarking lowers out-of-pocket Part B drug costs. Watch for manufacturer legal challenges and for whether CMS finalizes the reference-country price list it names.

Technical Levels and Sentiment

For the broad market, the S&P 500’s 52-week high of 7,785.76 is the immediate resistance level, with the August consolidation near that peak as a reference range; the 52-week low of 6,368.85 remains a deep support marker. The Nasdaq’s Friday close was itself a 52-week high at 27,190.86, leaving no overhead resistance from the trailing year. Medicare drug-pricing headlines rarely move major indexes the way they affect retiree cash-flow planning, so the more relevant read-through is to defensive and income-oriented sectors.

Risks and Catalysts

The main household-level risk is the gap between gross COLA and net deposit: a higher COLA can trigger a higher IRMAA tier for beneficiaries whose income rose, producing a smaller check despite a bigger raise. The missing October 2025 CPI data adds bracket uncertainty of as much as $1,000 at the threshold. On the drug side, the GLOBE model’s 25% geographic footprint means most beneficiaries will not see reduced coinsurance, and mandatory participation invites legal pushback from manufacturers.

The Medicare Trustees Report projects the 2027 standard premium at $209.50, up from $202.90 in 2026, while private forecasters expect $216 to $219. Because the 2027 COLA forecast is tracking near 3.5%, the net raise landing in most beneficiaries’ January deposits will be modest either way. I expect the binding CMS November figure to land above the $209.50 Trustees projection, in the $213 to $219 range, because the Trustees’ estimate has repeatedly run below the final number and drug spending growth continues to outpace the assumptions behind it. I also expect the 2027 COLA to be announced on October 14 at between 3.4% and 3.7%, because three-month CPI-W inflation through September has run in the mid-3% range. Both numbers will be settled before the January deposit arrives, which is the only figure that ultimately matters for a retiree’s budget.

Related Reading

More in-depth coverage from this blog on closely related topics:

• Liquidia Court Ruling Impacts LQDA Stock
• What Happens If You Owe Billions

Sources and References

Sources cited while researching and writing this article:

• Fact Sheet: President Donald J. Trump Announces Medicare Improvement Fund Payments for Seniors – The White House
• Medicare 2027 Projections: Higher Premiums Are Coming, but There’s Good News
• Projected 2027 IRMAA Brackets and Surcharges for Parts B and D
• CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs | AJMC